allogenic umbilical cord-derived mesenchymal stromal cells

This is an investigational cell therapy being developed by the University of Chile for the treatment of osteochondral lesions of the talus (OLT). The active ingredient consists of allogenic (donor-derived) mesenchymal stromal cells (MSCs) obtained from umbilical cord tissue. The therapy is administered as part of a combination treatment approach where the cells are embedded in a platelet-poor plasma (PPP) scaffold and applied to the lesion site following arthroscopic debridement and microfracture procedures. The biological objective is to promote the regeneration of high-quality hyaline-like cartilage and subchondral bone, potentially offering superior clinical and imaging outcomes compared to the fibrocartilage that typically forms after standard microfracture treatment alone. It is currently being evaluated in a Phase 3 clinical trial.

Other names

allogenic mesenchymal stromal cells derived from the umbilical cordumbilical cord-derived mesenchymal stem cellsUC-MSCsallogenic stromal mesenchymal cells-University of Chile-osteochondral lesion of the talus